American Airlines and its regional airline partner American Eagle serve almost 250 cities around the world, from Abilene to Zurich, and operate more than 3,600 daily flights. American Airlines is the largest domestic U.S. airline and American Eagle is the largest regional airline system in the world. American Airlines and American Eagle are in business to provide safe, dependable and friendly air transportation to our customers, along with numerous related services. Your safety, comfort, and convenience are our most important concerns. To learn more on how you can earn extra AAdvantage Airmiles AND support cancer research, click HERE.

Founded in 1907, the American Association for Cancer Research is a professional society of more than 24,000 laboratory, translational, and clinical scientists engaged in all areas of cancer research in the United States and in more than 60 other countries. AACR's mission is to accelerate the prevention and cure of cancer through research, education, communication, and advocacy. Its principal activities include the publication of five major peer-reviewed scientific journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention. AACR's Annual Meetings attract nearly 16,000 participants who share new and significant discoveries in the cancer field. Specialty meetings, held throughout the year, focus on the latest developments in all areas of cancer research. For more information, click HERE.

Accelrys is the world’s leading computational science company, developing and delivering innovative scientific software applications and services that help to solve critical R&D problems.  For more information, click HERE.

The Asian Fund for Cancer Research, Limited (AFCR) is committed to fighting cancer through research into the prevention, diagnosis, and treatment of cancer. AFCR is dedicated to achieving one of medicine's greatest goals: curing cancer to save lives. We fulfill this mission by funding outstanding scientists across Asia who pioneer cancer research and by providing prevention education programs to the general public. For more information click HERE.

Cancer Consultants is dedicated to providing the most up to date cancer information on the treatment and prevention of cancer for patients and professionals. For more information, click HERE.

The Chinese Biopharmaceutical Association (CBA) is a non-profit organization of professionals in the areas of bio-pharmaceutical research and technology development. It was established in the Spring of 1995 with its headquarters located in the State of Maryland adjacent to the U.S. capital city, Washington D.C. The majority of CBA members are Chinese scientists, researchers, or professors working in government agencies, universities, research institutes, and biotechnology and pharmaceutical industries. Among them, many are doing pioneering research with the National Institutes of Health (NIH), and some are directly involved in the government regulatory process as officers of the Food and Drug Administration. CBA's Executive Committee consists of research, regulatory and management professionals representing all sectors of the bio-pharmaceutical research and development institutions as well as regulatory agencies. These committee members have volunteered to contribute their time and skills to the founding and development of CBA.  For more information, click HERE.

DNA testing leader since 1987, providing accurate, convenient, affordable, confidential DNA testing, including pharmacogenetic testing, and the highest level of service. For more information, click HERE.

Inhibox is a drug discovery company that uses computational methods to discover new leads for drugs. The company's technology is based on the leveraging of computing power from individual PCs around the world. It uses novel software developed to screen libraries of molecules to search for suitable drug candidates; this type of software has been the basis of the hugely successful "cancer screensaver" project which now involves over one million PCs in 200 countries. Inhibox will also facilitate the considerable amount of chemical and biological testing that will be necessary to license such candidates to companies capable of exploiting their medicinal properties. For more information, click HERE.

The Programme of Action for Cancer Therapy (PACT) was created by the International Atomic Energy Agency (IAEA) in 2004 in response to the developing world’s growing cancer crisis. Drawing on the IAEA’s 30 years experience in radiation medicine and technology, PACT aims to help developing countries build a comprehensive, sustainable cancer control programme integrating prevention, screening, treatment and palliative care.

PACT seeks to raise cancer awareness, assess needs, develop demonstration projects and attract donors. PACT also aims to work with leading cancer organisations to develop joint programmes and raise funds for cancer care where they are most needed. PACT believes such public-private partnerships are essential to address future cancer needs in the developing world. For more information, click HERE.

Molecular Profiling is a CLIA certified specialty reference laboratory that helps patients worldwide by applying the discoveries of the Human Genome Project to personalized medicine. Molecular Profiling provides cutting-edge testing facilities, products, and resources for genomic and proteomic profiling and treatment of complex diseases, and pharmaceutical services to identify populations that may respond to targeted therapies. Molecular Profiling leverages strategic relationships with a number of organizations including AmeriPath, Inc., the International Genomics Consortium (IGC), and the Translational Genomics Research Institute (TGen). For more information, click HERE.

The Prostate Cancer Foundation (PCF) is the world's largest philanthropic source of support for prostate cancer research. Founded in 1993, the PCF has raised more than $300 million and provided funding for prostate cancer research to more than 1,400 researchers at 100 institutions worldwide. The PCF has a simple, yet urgent goal: to find better treatments and a cure for recurrent prostate cancer. For more information, click HERE.

Systems Medicine, Inc. (SMi) develops oncology products by integrating predictive cellular pharmacogenomics (“omics”) with world-class clinical and regulatory expertise. This allows SMi to develop patient-selective therapies by defining the “context-of-vulnerability” of cancer and treating only those patients most likely to respond to specific drugs or drug combinations. The Company's business plan is to acquire clinical stage products, assess the context-of-vulnerability for those drugs, and optimally position those drugs for success in clinical development and commercial use. For more information, click HERE.

The Translational Genomics Research Institute (TGen) is a non-profit 501(c)(3) organization focused on developing earlier diagnostics and smarter treatments. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases. TGen's research is based on personalized medicine. The institute plans to accomplish its goals through robust and disease-focused research. For more information, click HERE.